Merck & Co Inc is to partner with NGM Biopharmaceuticals Inc to build its capabilities in the area of therapies for metabolic diseases. The collaboration covers several preclinical candidate drugs including one for diabetes, obesity and non-alcoholic steatohepatitis.
